Technical Analysis for IMM - Immupharma Plc

Grade Last Price % Change Price Change
D 9.7 4.53% 0.42
IMM closed up 4.53 percent on Friday, April 16, 2021, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical IMM trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Fell Below 50 DMA Bearish 4.53%
Upper Bollinger Band Walk Strength 4.53%
Multiple of Ten Bearish Other 4.53%
Outside Day Range Expansion 4.53%
Older End-of-Day Signals for IMM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 10 DMA 1 day ago
50 DMA Support 1 day ago
Rose Above 50 DMA 1 day ago
20 DMA Support 1 day ago
Down 3% 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immupharma Plc Description

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Research Pain Medicine Clinic Cement Disease Earl Cancer Diseases Medical Specialties Drugs Mr Drug Discovery Disorders Autoimmune Diseases Infection Antibiotic Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus

Is IMM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 21.3909
52 Week Low 8.1
Average Volume 1,845,499
200-Day Moving Average 11.80
50-Day Moving Average 9.24
20-Day Moving Average 9.11
10-Day Moving Average 9.47
Average True Range 0.86
ADX 34.65
+DI 16.98
-DI 8.89
Chandelier Exit (Long, 3 ATRs ) 7.91
Chandelier Exit (Short, 3 ATRs ) 10.70
Upper Bollinger Band 10.07
Lower Bollinger Band 8.16
Percent B (%b) 0.81
BandWidth 21.01
MACD Line 0.12
MACD Signal Line 0.01
MACD Histogram 0.1081
Fundamentals Value
Market Cap 24.27 Million
Num Shares 250 Million
EPS -5.10
Price-to-Earnings (P/E) Ratio -1.90
Price-to-Sales 168.34
Price-to-Book 5.29
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.75
Resistance 3 (R3) 10.63 10.17 10.58
Resistance 2 (R2) 10.17 9.90 10.23 10.52
Resistance 1 (R1) 9.93 9.73 10.05 10.05 10.46
Pivot Point 9.47 9.47 9.53 9.53 9.47
Support 1 (S1) 9.23 9.20 9.35 9.35 8.94
Support 2 (S2) 8.77 9.03 8.83 8.88
Support 3 (S3) 8.53 8.77 8.83
Support 4 (S4) 8.65